Source: Pharmaceutical Technology
Source: Pharmaceutical Technology
The audience at the 2-23 ASCO Annual Meeting. Positive results have motivated Eclipse to accelerate its RET inhibitorRET inhibitor pipeline. Credit: Photo by © ASCO/Todd Buchanan 2023. How is the Biopharmaceutical industry evolving?
2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.
Benchmark the impact of major themes on the Biopharmaceutical industry.
Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success.
Source: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
-->By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Submit
Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Please check your email to download the Report.
Following the publication of clinical data from its Phase I study of the inhibitor at the American Society of Clinical Oncology (ASCO) conference, Ellipses was motivated to accelerate clinical development due to what it believes are “very encouraging” results. The ASCO Annual Meeting is being held 2–6 June in Chicago.
Source: Pharmaceutical Technology
Source: Pharmaceutical Technology
View allCompanies IntelligenceEllipses Pharma LtdView all
Ellipses reported preliminary efficacy and safety data for the 109 patients enrolled in the trial. For the RET-altered tumour population, patients receiving doses of 40-120mg had an objective response rate (ORR) of 60%, and a disease control rate of 90%. Two patient cohorts were highlighted in particular. The first, patients, with previously untreated RET-fusion positive advanced NSCLC, had an ORR of 80.8%. Another cohort of patients with RET-fusion positive NSCLC who had received treatment like chemo-immunotherapy, had an ORR of 69.7%. In both cases, DCR of over 96% were reported. Dr. Tobias Arkenau, Global Head of Drug Development & CMO at Ellipses, said the data gives Ellipses the backing to advance their pipeline. The company was also eager to highlight observed evidence of clinical activity in patients with brain metastases. It also saw similar for patients who had previously been treated with first-generation SRIs, who currently have limited available treatment options.
The cohorts were part of a global, modular phase I/II trial in patients with advanced RET-altered tumours (add NCT). Data released at this point will be augmented by the results of ongoing trials in the US, EU, and UK
How is the Biopharmaceutical industry evolving?
2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.
Benchmark the impact of major themes on the Biopharmaceutical industry.
Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success.
Source: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
-->By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Submit
Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Please check your email to download the Report.